

Cutaquig SCIG Therapy Patient Referral and Prescription

То:	From:		Pho	Phone:	
Intake phone: 734.425.2550	Fax: Numb		Number of	er of Pages (Including Cover):	
Date: DOB:		Allergies:	1		
Patient Name:	ŀ	leight:		Weight:	
 Begin Cutaquig SCIG per KabaFusion protocol formonths Begin Cutaquiggrams SCIG everyformonths KabaFusion to provide infusion pump needle administration sets (A4221) KabaFusion to provide infusion supplies for infusion pump (K0552) KabaFusion to provide mechanical ambulatory infusion pump (E0779) Infusion RN home visit prior to therapy start to assess patient and home environment, educate patient about SCIG therapy. Infusion RN visits x 3 and PRN to educate patient to self administer Cutaquig infusion KabaFusion to provide all professional services related to infusion 					
Diagnosis:					ICD-10
Common Variable Immunodeficiency with Predominant Immunoregulatory T-Cell Disorders					D83.1
Wiskott-Aldrich Syndrome					D82.0
Combined Immunodeficiency, Unspecified					D81.9
Severe Combined Immunodeficiency [SCID] with Low T- and B- Cell Numbers					D81.1
Severe combined Immunodeficiency [SCID] with Low or Normal B-Cell Numbers					D81.2
Selective deficiency of Immunoglobulin A IgA]					D80.2
Selective deficiency of Immunoglobulin M [IgM]					D80.4
Selective deficiency of Immunoglobulin G [IgG] Subclasses					D80.3
Hereditary Hypogammaglobulinemia					D80.0
Immunodeficiency with Increased IgM					D80.5
Other Common Variable Immunodeficiencies					D83.8
Common Variable Immunodeficiency, Unspecified					D83.9
Other:					
Premedication Orders: Refill x 1Year				5 MG orally PRE-SCIG	
Refill x 1Year Other: Per KabaFusion recommendation: Epinephrine 0.3mg 2-Pak Auto-Injector ACETAMINOPHEN 650 MG (325mg X 2) orally PRE-SCIG None					
Prescriber Signature:Date					
Print Prescriber Name:NPI#					
Please fax the following information:					
The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure. If you are not the intended ercipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you. KabaFusion Infusion Pharmacy 28550 Cabot Drive Suite 200 Novi, MI 48150 Phone: 734.425.2550 Fax: 734.425.0470 <u>wwww.kabafusion.com</u>					